lisocabtagene maraleucel
bms
['lymphoma', 'liso-cel', 'dlbcl']
 presenting on responses to checkpoint inhibitor therapy after post car-t relapse - survival is poor although perhaps improved in pmbcl and better when combined with other therapies. proud to see a alumnus on the stage!! #ash22 
Heme/Onc fellow @UChicagoMed, alumna of @MedChiefs @UCSFMedicine @Harvard. Views are my own.